Navigation Links
Blood test could predict metastasis risk in melanoma
Date:4/14/2011

PHILADELPHIA Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"The rate at which melanoma is increasing is dramatic, and there is a huge number of patients under surveillance," said Harriet Kluger, M.D., associate professor of medicine at Yale University School of Medicine. "Our current method of surveillance includes periodic imaging, which creates huge societal costs."

Melanoma is the fifth most common cancer in men and the seventh most common cancer in women. It is estimated that 68,130 people in the United States were diagnosed in 2010, and 8,700 died. With proper screening, melanoma can often be caught early enough to be removed with surgery, and mortality typically comes when the cancer metastasizes. The risk of metastasis varies from less than 10 percent for those with stage 1A melanoma, to as high as 70 percent with stage 3C.

Patients with melanoma are typically subjected to a combination of imaging tests, blood tests and physical examinations, but there is no clear consensus on how often these tests should occur or how reliable they are.

Kluger and colleagues tested the plasma of 216 individuals, including 108 patients with metastatic melanoma and 108 patients with stage 1 or 2 disease. They identified seven plasma biomarkers: CEACAM, ICAM-1, osteopontin, MIA, GDF-15, TIMP-1 and S100B.

All of these biomarkers were higher in patients with metastatic melanoma than patients with early-stage disease. In fact, 76 percent of patients with early-stage disease had no elevations at all whereas 83 percent of metastatic patients had elevations of at least one marker. Researchers calculated that the area under the curve, a measure of the test's reliability, was 0.898. Area under the curve calculations rate from .5 to 1, with 1 being optimal and .5 being useless.

"This finding will need to be confirmed prospectively before it is used in the clinic, but it shows that such testing is possible," said Kluger.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. New ACE survey shows people with type 2 diabetes experience low blood sugar during typical daily activities
2. Brisk Walk Can Boost Blood Flow to the Brain: Report
3. Higher Rate of Morning Heart Attacks Not Due to Blood Pressure: Study
4. Research shows blood protein levels may predict risk of a cardiovascular event: Study
5. Blood Marker Suggests Severity of Alzheimers Disease
6. Device drops blood pressure in patients with difficult-to-treat hypertension
7. Dangerous blood pressure increases during exercise can be blocked, UT Southwestern researchers find
8. Blood Test Holds Hope for Spotting Lung Cancer in Nonsmokers
9. University of Cincinnati team to track tumor DNA through bloodstream
10. CDC issues updated bloodstream infection prevention guidelines
11. Remove childrens catheters as soon as possible to prevent bloodstream infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: